MYGN's Quality Score fell 1 point on Fri, Nov 6, to 4. Buying slipped from its highest in 20 days (2 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 32% on Oct 20, and still 41% over its Oct 19 close.
“This transaction is expected to be accretive to Myriad’s revenue growth and profitability”
| Holding it back | Sales down 3% on the year |
| Latest filing | 8-K, Nov 4 |
Labcorp acquires Myriad Genetics Prenatal Health testing unit in strategic deal
MYGN closed +31.6% that day on 13.1x normal volume.
Tue Nov 10: UBS Global Healthcare Conference 2026Investor conference · date confirmed.
2 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed -14.8% on average, higher 2 of 4 times.
Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
MYGN is #35 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 35 |
Expected to report Tue Feb 23, after the close (in 106 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $202.7M, 1% less than a year ago; a loss of $0.46 a share, from $0.29.
“Higher Cancer Care Continuum (CCC) product mix and continued progress on payer engagement and revenue cycle management initiatives drove total average revenue per test increases of 7% sequentially and 1% year-over-year, partially offset by total test volume declines of 1% and 2%, respectively.”
MYGN's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Third quarter 2026 gross margin was 67.9%, down 200 basis points from the third quarter 2025, reflecting lower overall test volumes and incremental investments in laboratory personnel.”
From its results filing (SEC filing · Nov 4)
Sales grew 8.2% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 4.4% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +6.5% | +4.5% | not yet |
| Jul 30, 2026 | -42.3% | -46.7% | -40.8% |
| May 5, 2026 | -17.9% | -18.3% | -19.1% |
Sales grew in three of the last five years, to $825M in 2025. It lost money in each of the six years.
RSI 59.0, MACD below signal, above both averages. Not scored.
One insider bought $28K across 1 filing in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: MYGN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
MYGN scores 4 today, which Breakaway calls Below Average. It is #35 of 90 in Pharma by Quality Score, with 3 of 14 chart checks firing. Up 32% on Oct 20, and still 41% over its Oct 19 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
MYGN scores 4 today, which Breakaway calls Below Average (0 to 5). That is #35 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MYGN's 4.
One insider bought $28K across 1 filing in the last 6 months. No open-market sales on record. The newest is Paul Bisaro, Director, who bought $28K on May 14.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.